Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BACE1 | P56817 | 20/20 | 0.50 |
| ▸ | CTSD | P07339 | 18/20 | 0.50 |
| ▸ | BACE2 | Q9Y5Z0 | 18/20 | 0.50 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.48 |
| ▸ | CYP2D6 | P10635 | 3/20 | 0.48 |
| ▸ | CYP2C9 | P11712 | 3/20 | 0.48 |
| ▸ | CYP2C19 | P33261 | 3/20 | 0.48 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3345281 | 1.00 | BACE1 (0.50) | BACE1CTSDBACE2CYP3A4CYP2D6 | |
| SCHEMBL3344441 | 0.94 | BACE1 (0.52) | BACE1CTSDBACE2CYP3A4CYP2D6 | |
| SCHEMBL3341426 | 0.94 | BACE1 (0.52) | BACE1CTSDBACE2CYP3A4CYP2D6 | |
| SCHEMBL3341431 | 0.94 | BACE1 (0.52) | BACE1CTSDBACE2CYP3A4CYP2D6 | |
| SCHEMBL3348092 | 0.94 | BACE1 (0.52) | BACE1CTSDBACE2CYP3A4CYP2D6 | |
| SCHEMBL3344438 | 0.94 | BACE1 (0.52) | BACE1CTSDBACE2CYP3A4CYP2D6 | |
| SCHEMBL3348101 | 0.94 | BACE1 (0.52) | BACE1CTSDBACE2CYP3A4CYP2D6 | |
| SCHEMBL3347578 | 0.94 | BACE1 (0.51) | BACE1CTSDBACE2CYP3A4CYP2D6 | |
| SCHEMBL3347581 | 0.94 | BACE1 (0.51) | BACE1CTSDBACE2CYP3A4CYP2D6 | |
| SCHEMBL3341738 | 0.90 | BACE1 (0.47) | BACE1CTSDBACE2CYP3A4CYP2D6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2185525-B1 | PYRAZOLE 3,5 CARBOXYLATE DERIVATIVES PREPARATION AND THERAPEUTIC APPLICATION THEREOF | SANOFI SA (FR) | 2016-12-14 | — | — | EP | disclosed |
| US-9102628-B2 | Derivatives of pyrazole 3,5-carboxylates, their preparation and their application in therapeutics | SANOFI (FR) | 2015-08-11 | — | — | US | disclosed |
| US-20100160377-A1 | DERIVATIVES OF PYRAZOLE 3,5-CARBOXYLATES, THEIR PREPARATION AND THEIR APPLICATION IN THERAPEUTICS | SANOFI-AVENTIS (FR) | 2010-06-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100160377-A1 | DERIVATIVES OF PYRAZOLE 3,5-CARBOXYLATES, THEIR PREPARATION AND THEIR APPLICATION IN THERAPEUTICS | CYP3A5, ADH5, AVPR2 | BACE1 3223/4885CTSD 2356/4885BACE2 4244/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.